Article ID Journal Published Year Pages File Type
5700240 Clinical Oncology 2009 7 Pages PDF
Abstract
This single-centre study reflects the outcome of unselected consecutively treated non-small cell lung cancer patients. Adjusting for stage, there was no significant difference in survival seen according to regimen. Encouragingly, CHART outcome shows reproducibility with the original CHART paper. Our hypofractionated outcome is similar to that previously reported, but despite this being the UK's most common regimen, 55 Gy in 20 daily fractions remains unvalidated by phase III trial data.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , ,